SCHEMBL10201993

SCHEMBL10201993

CC(=O)c1ccc2cnccc2n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
MGAM O43451 1/20 0.39
CNR2 P34972 2/20 0.39
CNR1 P21554 1/20 0.39
ROCK2 O75116 1/20 0.38
HASPIN Q8TF76 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
HDAC8 Q9BY41 1/20 0.36
IMPDH2 P12268 1/20 0.36
HPGD P15428 1/20 0.36
ACKR3 P25106 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27776426 0.85 KDM4E (0.50) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL1016413 0.83 MGAM (0.58) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL3282791 0.81 ADORA3 (0.46) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL4894481 0.81 CTSA (0.42) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL12664041 0.81 CTSA (0.43) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL327145 0.81 ALDH1A1 (0.46) CTSAHDAC3HDAC1HDAC2ROCK2
SCHEMBL4729283 0.77 ALDH1A1 (0.63) CTSAHDAC3HDAC1HDAC2ALDH1A1
SCHEMBL28187527 0.77 CTSA (0.40) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL2445721 0.77 CYP1A2 (0.54) CTSAHDAC3HDAC1HDAC2ALDH1A1
SCHEMBL29852425 0.77 CTSA (0.40) CTSAHDAC3HDAC1HDAC2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
WO-2011058474-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
US-7790713-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-07 US disclosed
US-7790713-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B CTSA 167/4885HDAC3 1734/4885HDAC1 1192/4885
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B CTSA 167/4885HDAC3 1734/4885HDAC1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.